HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark D P Willcox Selected Research

Contact Lenses

1/2022A rationally designed synthetic antimicrobial peptide against Pseudomonas-associated corneal keratitis: Structure-function correlation.
12/2021Controlled bimatoprost release from graphene oxide laden contact lenses: In vitro and in vivo studies.
10/2021Susceptibility of Ocular Staphylococcus aureus to Antibiotics and Multipurpose Disinfecting Solutions.
7/2021The Autofluorescence Patterns of Acanthamoeba castellanii, Pseudomonas aeruginosa and Staphylococcus aureus: Effects of Antibiotics and Tetracaine.
2/2021Risk Factors for Contact Lens-Related Microbial Keratitis and Associated Vision Loss in a South Indian Population.
1/2021Effect of Antimicrobial Contact Lenses on Corneal Infiltrative Events: A Randomized Clinical Trial.
1/2021American Academy of Optometry Microbial Keratitis Think Tank.
1/2020The Development of an Antimicrobial Contact Lens - From the Laboratory to the Clinic.
1/2019The Effect of Microblepharon Exfoliation on Clinical Correlates of Contact Lens Discomfort.
10/2018Development of Silicone Hydrogel Antimicrobial Contact Lenses with Mel4 Peptide Coating.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark D P Willcox Research Topics

Disease

41Keratitis
01/2022 - 01/2002
31Infections
03/2022 - 02/2003
7Eye Infections
01/2022 - 05/2002
7Inflammation (Inflammations)
02/2021 - 05/2002
6Bacterial Infections (Bacterial Infection)
04/2022 - 05/2003
6Keratoconus
01/2022 - 03/2010
5Dry Eye Syndromes (Dry Eye Syndrome)
01/2022 - 12/2014
5Conjunctivitis
10/2021 - 01/2002
4Type 2 Diabetes Mellitus (MODY)
01/2020 - 03/2010
3Pseudomonas Infections
01/2022 - 01/2007
3Myopia
01/2011 - 12/2009
3Ulcer
01/2010 - 07/2003
2Glaucoma
12/2021 - 01/2021
2Acanthamoeba Keratitis
07/2021 - 01/2010
2Peripheral Nervous System Diseases (PNS Diseases)
01/2020 - 10/2019
2Pain (Aches)
02/2017 - 01/2017
2Diabetic Retinopathy (Retinopathy, Diabetic)
03/2015 - 08/2010
2Necrosis
03/2013 - 03/2010
2Wounds and Injuries (Trauma)
07/2008 - 09/2006
2Corneal Injuries
10/2007 - 05/2003
2Blindness (Hysterical Blindness)
01/2007 - 06/2005
1Headache (Headaches)
01/2022
1Hypersensitivity (Allergy)
01/2022
1Pterygium
01/2022
1Uveitis
01/2021
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
10/2019
1Blepharitis
01/2019
1Blister (Bulla)
09/2018
1Metaplasia
11/2017
1Disease Progression
05/2017
1Diabetes Mellitus
03/2015
1Flushing
12/2014

Drug/Important Bio-Agent (IBA)

14Anti-Bacterial Agents (Antibiotics)IBA
03/2022 - 06/2005
8Proteins (Proteins, Gene)FDA Link
10/2016 - 10/2008
7Antimicrobial PeptidesIBA
04/2022 - 12/2012
7HydrogelsIBA
01/2021 - 01/2002
7CytokinesIBA
11/2017 - 01/2002
7Virulence Factors (Pathogenicity Factors)IBA
10/2016 - 12/2002
7Peptide Hydrolases (Proteases)FDA Link
03/2013 - 01/2002
5SiliconesIBA
01/2021 - 03/2008
5Interleukin-6 (Interleukin 6)IBA
11/2017 - 02/2003
4ChemokinesIBA
10/2014 - 01/2007
3Biocompatible Materials (Biomaterials)IBA
03/2022 - 01/2009
3Pharmaceutical PreparationsIBA
12/2021 - 07/2021
3LipidsIBA
01/2021 - 12/2014
3FluoroquinolonesIBA
11/2020 - 03/2008
3melimineIBA
10/2020 - 04/2016
3Biomarkers (Surrogate Marker)IBA
10/2019 - 03/2010
3Matrix Metalloproteinases (MMPs)IBA
03/2013 - 05/2003
3InterleukinsIBA
03/2013 - 03/2010
3Interleukin-4 (Interleukin 4)IBA
06/2007 - 06/2005
2Ciprofloxacin (Cipro)FDA LinkGeneric
10/2021 - 03/2011
2Oxygen (Dioxygen)IBA
01/2021 - 03/2008
2NAD (NADH)IBA
01/2020 - 10/2019
22-(4-toluidino)-6-naphthalenesulfonic acid (TNS)IBA
01/2020 - 10/2019
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2017 - 03/2010
2Interleukin-10 (Interleukin 10)IBA
11/2017 - 06/2005
2Anti-Infective Agents (Microbicides)IBA
11/2016 - 01/2002
2tear proteinsIBA
01/2016 - 01/2013
2Polysaccharides (Glycans)IBA
01/2016 - 03/2015
2Messenger RNA (mRNA)IBA
10/2014 - 10/2010
2Interleukin-8B ReceptorsIBA
10/2014 - 01/2007
2AlbuminsIBA
03/2010 - 01/2002
2Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
03/2010 - 10/2007
2SolutionsIBA
01/2010 - 12/2009
2HCEIBA
04/2007 - 02/2007
1Cholic AcidIBA
04/2022
1Peptides (Polypeptides)IBA
01/2022
1Bimatoprost (Lumigan)FDA Link
12/2021
1Chloramphenicol (Chloromycetin)FDA Link
10/2021
1Oxacillin (Prostaphlin)FDA LinkGeneric
10/2021
1Toll-Like Receptors (Toll-Like Receptor)IBA
06/2021
1Superoxides (Superoxide)IBA
01/2021
1Lubricant Eye Drops (Artificial Tears)IBA
01/2021
1Free RadicalsIBA
01/2021
1EndotoxinsIBA
01/2021
1Adenosine Monophosphate (AMP)IBA
09/2020
1Substance PIBA
10/2019
1Calcitonin Gene-Related PeptideIBA
10/2019
1Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2018
1Biological ProductsIBA
12/2018
1Povidone (Crospovidone)IBA
09/2018
1Phosphates (Orthophosphate)IBA
09/2018
1Interleukin-17 (Interleukin 17)IBA
11/2017
1Protamines (Protamine Sulfate)FDA Link
11/2016
1ProteomeIBA
10/2016
1TitaniumIBA
04/2016
1Complement System Proteins (Complement)IBA
01/2016
1PyocyanineIBA
10/2015
1Peroxidase (Myeloperoxidase)IBA
10/2014
1Platelet Endothelial Cell Adhesion Molecule-1IBA
10/2014
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
10/2014
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
10/2014

Therapy/Procedure

47Contact Lenses
01/2022 - 01/2002
7Lenses
12/2021 - 01/2002
7Therapeutics
11/2020 - 01/2002
2Aftercare (After-Treatment)
01/2019 - 02/2007
1Laser In Situ Keratomileusis (LASIK)
01/2022
1Denervation
10/2019
1Phakic Intraocular Lenses
05/2017